Needham & Company reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); Mgmt Changes Not Related to Dificid

Needham & Company reiterates a 'Buy' on Optimer Pharmaceuticals (NASDAQ: OPTR) price target of $19.00.

Analyst, Alan Carr, said, despite the removal of certain executive manangement members, including CFO, Chairman/Founder, the company is still on track with the development and commercialization of Dificid. Apparently, previously granted shares of the Opimer Biotech subsidiary (1.5 mln) were at the root of the dismissal of the executives, but the Carr feels the matter does not conflict with the Company's product(s).

For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.

Shares of Optimer Pharmaceuticals closed at $14.29 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Coherent (COHR) PT Raised to $420 at Needham
• Alpha & Omega Semiconductor (AOSL) PT Lowered to $45 at Needham
• Needham Reiterates Hold Rating on CoreWeave (CRWV)